Sepsis Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Global Sepsis Market is Segmented by Technology (Molecular Diagnostics, Microbiology, Immunoassay, and Other Technologies), Product (Instruments, Assays and Reagents, and Other Products), Diagnostic Method (Conventional Diagnostics and Automated Diagnostics), Pathogen (Bacterial Sepsis, Fungal Sepsis, and Other Pathogens), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market size and forecasts are provided in terms of value (in USD million) for the above segments.

Sepsis Diagnosis Market Size

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:
Sepsis Diagnostics Market Summary
Study Period 2019 - 2029
Market Size (2024) USD 0.74 Billion
Market Size (2029) USD 1.02 Billion
CAGR (2024 - 2029) 6.58 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

Sepsis Diagnostics Market Major Players

*Disclaimer: Major Players sorted in no particular order

setting-icon

Need a report that reflects how COVID-19 has impacted this market and its growth?

Single User License

$4750

Team License

$5250

Corporate License

$8750

Book before:

Sepsis Diagnosis Market Analysis

The Global Sepsis Diagnostics Market size is estimated at USD 0.74 billion in 2024, and is expected to reach USD 1.02 billion by 2029, growing at a CAGR of 6.58% during the forecast period (2024-2029).

Increasing incidences of sepsis in COVID-19 patients is anticipated to have a positive impact on the market studied. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', the analysis of the 2020 acute care hospitals standardized infection ratios found significant increases in central line-associated bloodstream infections, catheter-associated urinary tract infections, ventilator-associated events, and methicillin-resistant Staphylococcus aureus bacteremia compared to 2019. The largest increases occurred during quarter 4 of 2020. Furthermore, according to a study published by PLOS in August 2021, 'Immunometabolic signatures predict the risk of progression to sepsis in COVID-19,' COVID-19 patients are at the highest risk of developing sepsis. Hence, this is expected to create new opportunities for novel diagnosis in the market studied.

The major factors for the growth of the sepsis diagnostics market include the increasing burden of sepsis, the growing burden of hospital-acquired infections, the increasing number of pneumonia cases, the rise in the number of sepsis procedures, and an increase in funding for sepsis-related research activities. Hospital-acquired infections (HAIs) are the most common complications among hospitalized patients. For instance, according to a report published by the Centers for Disease Control and Prevention (CDC) in 2021, '2020 National and State Healthcare-Associated Infections Progress Report', about 24%, 35%, and 15% increase in central line-associated bloodstream infections, ventilator-associated events, and Methicillin-resistant Staphylococcus Aureus (MRSA) bacteremia between 2019 and 2020 in the United States. The rising bloodstream infections will lead to increased adoption of sepsis diagnostic products. Additionally, in June 2021, the collaboration led by the University of Liverpool has received more than GBP 3 million in funding for a new intervention that will actively prevent, treat and evaluate maternal sepsis.

Thus, the rise in the prevalence of sepsis and increase in funding for research activities for sepsis diagnosis are expected to drive the overall growth of the sepsis diagnosis market over the forecast period.

Sepsis Diagnosis Market Trends

This section covers the major market trends shaping the Sepsis Diagnostics Market according to our research experts:

The Molecular Diagnostics Segment Has a Significant Share in the Market

Sepsis affects significant patient populations in hospitals and is the sixth most common reason for hospitalization. Rapid and accurate profiling of infection-causing pathogens remains a significant challenge in modern healthcare. Moreover, identification of the causative pathogen is essential in selecting appropriate antibiotic therapy as part of the treatment. These requirements make molecular diagnostics (MDx) an attractive approach to consider for sepsis diagnostics.

Molecular diagnostics have attracted several multinational companies and institutions, owing to their easy feasibility and accuracy in detection methods. The blood culture analysis for rapid and accurate profiling of infections has been the gold standard for the molecular diagnostic method. However, the cost of molecular diagnostics has remained very high, as compared to conventional procedures, which restricts its market growth. Several companies are investing in point-of-care molecular diagnostics for the early diagnosis of bacterial and viral pathogens and better patient management. For instance, in October 2020, Immunexpress launched a rapid SeptiCyte, a one-hour molecular diagnostic test for sepsis in Europe on Biocartis' Idylla platform. This is one of the first rapid, fully-integrated, and immune response-based tests to aid clinicians with a sepsis diagnosis.

Furthermore, researchers are attempting to develop a molecular diagnostic that can detect the COVID-19 and sepsis, as well as discriminate between the two. In November 2020, the Hellenic Institute for the Study of Sepsis and, in part by Sanmina Corporation, funded a study and developed a novel optical biosensor for the early diagnosis of sepsis and severe COVID-19. These developments are expected to have a positive impact on the growth of this segment.

Sepsis Diagnostics Market - Serpis-related death rate among adults aged 65 and over (per 1000), Unites States, 2019

North America is Expected to Hold a Large Share of the Market

North America is found to hold a major share of the sepsis diagnostics market and is expected to show a similar trend over the forecast period, without significant fluctuations. According to the Centers for Disease Control and Prevention, in August 2021, approximately 1.7 million adults in America develop sepsis, and nearly 270,000 Americans die due to sepsis. It was also found that 1 in 3 patients who die in a hospital has sepsis. Thus, the high incidence rate of the disease in the country will boost its diagnosis, thus, boosting the market.

Moreover, rising investments in the fields of research and development for the diagnosis of sepsis will also boost the market. For instance, in April 2020, Cytovale Inc. expanded its partnership with the Biomedical Advanced Research and Development Authority (BARDA) for diagnosing sepsis in patients with potential respiratory infections, including COVID-19. The research is estimated to stand at the cost of USD 5.9 million, with approximately USD 3.83 contributed by the Biomedical Advanced Research and Development Authority (BARDA), thus, driving the market.

Therefore, the rising prevalence of sepsis and increasing investments in the research and development of sepsis diagnosis may augment the growth of the market in the United States.

Sepsis Diagnostics Market - Growth Rate by Region

Sepsis Diagnosis Industry Overview

The sepsis diagnostics market is moderately consolidated owing to the presence of a few key players. The market is expected to drive due to the products launched by the key players in the market and the rise in research initiatives on sepsis diagnostics by the key players. Some of the market players are Abbott, Becton, Dickinson, and Company, bioMérieux SA, Bruker Corporation, F. Hoffmann-LA Roche Ltd, and Immunexpress Inc., among others.

Sepsis Diagnosis Market Leaders

  1. Abbott

  2. Diasorin

  3. Becton, Dickinson, and Company

  4. bioMérieux SA

  5. F. Hoffmann-LA Roche Ltd

*Disclaimer: Major Players sorted in no particular order

Sepsis Diagnostics Market Concentration
Need More Details on Market Players and Competitors?
Download PDF

Sepsis Diagnosis Market News

  • In December 2021, Immunoexpress received the United States Food and Drug Administration (FDA) approval for SeptiCyte RAPID.
  • In October 2021, Prenosis Inc., a precision diagnostics firm that uses artificial intelligence to enhance clinical diagnosis, expanded its existing agreement with Roche Diagnostics to improve and speed the clinical detection of sepsis.

Sepsis Diagnosis Market Report - Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions and Market Definition

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Burden of Sepsis

      2. 4.2.2 Growing Incidence of Hospital-acquired Infections

      3. 4.2.3 Rise in the Number of Sepsis Procedures and Increase in Funding for Sepsis-related Research Activities

    3. 4.3 Market Restraints

      1. 4.3.1 High Cost of Automated Diagnostic Instruments

      2. 4.3.2 Lack of Well-established Reimbursement Policies for Sepsis

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION (Market Size by Value - USD million)

    1. 5.1 By Technology

      1. 5.1.1 Molecular Diagnostics

      2. 5.1.2 Microbiology

      3. 5.1.3 Immunoassay

      4. 5.1.4 Other Technologies

    2. 5.2 By Product

      1. 5.2.1 Instruments

      2. 5.2.2 Assays and Reagents

      3. 5.2.3 Other Products

    3. 5.3 By Diagnostic Method

      1. 5.3.1 Conventional Diagnostics

      2. 5.3.2 Automated Diagnostics

    4. 5.4 By Pathogen

      1. 5.4.1 Bacterial Sepsis

      2. 5.4.2 Fungal Sepsis

      3. 5.4.3 Other Pathogens

    5. 5.5 By Geography

      1. 5.5.1 North America

        1. 5.5.1.1 United States

        2. 5.5.1.2 Canada

        3. 5.5.1.3 Mexico

      2. 5.5.2 Europe

        1. 5.5.2.1 Germany

        2. 5.5.2.2 United Kingdom

        3. 5.5.2.3 France

        4. 5.5.2.4 Italy

        5. 5.5.2.5 Spain

        6. 5.5.2.6 Rest of Europe

      3. 5.5.3 Asia-Pacific

        1. 5.5.3.1 China

        2. 5.5.3.2 Japan

        3. 5.5.3.3 India

        4. 5.5.3.4 Australia

        5. 5.5.3.5 South Korea

        6. 5.5.3.6 Rest of Asia-Pacific

      4. 5.5.4 Middle-East and Africa

        1. 5.5.4.1 GCC

        2. 5.5.4.2 South Africa

        3. 5.5.4.3 Rest of Middle-East and Africa

      5. 5.5.5 South America

        1. 5.5.5.1 Brazil

        2. 5.5.5.2 Argentina

        3. 5.5.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Abbott Laboratories Inc.

      2. 6.1.2 Axis-Shield Diagnostics Ltd

      3. 6.1.3 Becton, Dickinson, and Company

      4. 6.1.4 BioMerieux SA

      5. 6.1.5 Bruker Corporation

      6. 6.1.6 Cube Dx GmbH

      7. 6.1.7 Danaher Corporation

      8. 6.1.8 EKF Diagnostics

      9. 6.1.9 F. Hoffmann-LA Roche Ltd

      10. 6.1.10 Immunexpress Inc.

      11. 6.1.11 Diasorin

      12. 6.1.12 Response Biomedical Corp.

      13. 6.1.13 Sysmex Corporation

      14. 6.1.14 T2 Biosystems Inc.

      15. 6.1.15 Thermo Fisher Scientific

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Sepsis Diagnosis Industry Segmentation

As per the scope of this report, sepsis diagnostics is the study of diagnosis of sepsis, which is a serious and life-threatening clinical condition that generally results from primary bacterial infection or, less frequently, from a fungal and/or viral infection. The sepsis diagnostics market is segmented by technology (molecular diagnostics, microbiology, immunoassay, and other technologies), product (instruments, assays and reagents, other products), diagnostic method (conventional diagnostics, automated diagnostics), pathogen (bacterial sepsis, fungal sepsis, other pathogens), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally. The report offers the value (in USD million) for the above segments.

By Technology
Molecular Diagnostics
Microbiology
Immunoassay
Other Technologies
By Product
Instruments
Assays and Reagents
Other Products
By Diagnostic Method
Conventional Diagnostics
Automated Diagnostics
By Pathogen
Bacterial Sepsis
Fungal Sepsis
Other Pathogens
By Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Sepsis Diagnosis Market Research FAQs

The Global Sepsis Diagnostics Market size is expected to reach USD 0.74 billion in 2024 and grow at a CAGR of 6.58% to reach USD 1.02 billion by 2029.

In 2024, the Global Sepsis Diagnostics Market size is expected to reach USD 0.74 billion.

Abbott, Diasorin, Becton, Dickinson, and Company, bioMérieux SA and F. Hoffmann-LA Roche Ltd are the major companies operating in the Global Sepsis Diagnostics Market.

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).

In 2024, the North America accounts for the largest market share in Global Sepsis Diagnostics Market.

In 2023, the Global Sepsis Diagnostics Market size was estimated at USD 694.39 million. The report covers the Global Sepsis Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Sepsis Diagnostics Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.

Sepsis Diagnostics Industry Report

Statistics for the 2024 Sepsis Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Sepsis Diagnostics analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!

Sepsis Diagnostics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)